hepatocellular carcinoma
Conditions
Interventions
Atezolizumab plus bevacizumab with carbon ion radiotherapy
Sponsors
Yamagata University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Age at which consent was obtained is 20 years or older Patients with unresectable hepatocellular carcinoma Child-Pugh classification: Class A Patients who are scheduled to receive atezolizumab/bevacizumab combination therapy in clinical practice based on the latest package insert and guidelines for promoting optimal use. Patients who received atezolizumab/bevacizumab combination therapy prior to the heavy ion therapy will be eligible for enrollment. Patients who have been fully informed of the details of the study and who have given their free and voluntary written consent.
Exclusion criteria
Exclusion criteria: Patients with untreated or poorly treated esophageal aneurysms and/or gastric varices with or judged to be at high risk for bleeding. Patients who have undergone esophagogastroduodenoscopy (EGD) prior to enrollment, have been examined and treated for varices, and have been determined to be at low risk for bleeding will be eligible for enrollment. (EGD will not be required if performed within 6 months prior to starting atezolizumab/bevacizumab combination therapy.) Patients who are deemed inappropriate by the principal investigator or study investigators to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Over survival+Progression-free survival for carbon ion radioherapy and Atezolizumab/Bevacizumab Combination Therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate and Incidence of side effects | — |
Countries
Japan
Contacts
Public ContactTomohiro Katsumi
Yamagata University Faculty of Medicine Department of Gastroenterology
Outcome results
None listed